Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01127633 · ClinicalTrials.gov registry record · Phase 3
Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease
A Phase 3 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,457
- Enrollment target
NCT01127633 is a Phase 3 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,457 participants.
The verdict
NCT01127633, a Phase 3 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,457 participants
- Enrollment target
Study Summary
This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).
Interventions
- DRUG Placebo
- DRUG Solanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,457 participants |
| Start Date | 2010-12 |
| Est. Completion | 2017-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01127633
The ClinicalTrials.gov registry entry for NCT01127633 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01127633 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01127633 about?
NCT01127633 is a clinical study titled "Continued Safety Monitoring of Solanezumab (LY2062430) in Alzheimer's Disease". This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM (NCT00905372) or H8A-MC-LZAN (NCT00904683).
What is the current status of trial NCT01127633?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,457 participants. The study started on 2010-12. Estimated completion is 2017-02.
What interventions are being tested in trial NCT01127633?
The interventions under investigation include: Placebo (DRUG), Solanezumab (DRUG).
Who is sponsoring clinical trial NCT01127633?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.